Concepedia

Thabata Veiga

TV

Statistics

Publications

7

Citations

1K

H-Index

7

Active since

2017

Affiliations

Alexion Pharmaceuticals (United States)(Current)

International University of Health and Welfare

National Hospital Organization Hanamaki Hospital

University of North Carolina at Chapel Hill

Fondazione IRCCS Istituto Neurologico Carlo Besta

Thabata Veiga is an author at Alexion Pharmaceuticals (United States) specializing in myasthenia gravis, pharmacotherapy, and anti-acetylcholine receptor antibodies.

Publications per year

2017–2025

7

Publications

7

Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study

James F. Howard, Kimiaki Utsugisawa, Michael Benatar et al. · The Lancet Neurology · 2017 · 800 citations

, , +6

Post-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension

Renato Mantegazza, Gil I. Wolfe, Srikanth Muppidi et al. · Neurology · 2020 · 79 citations · Full text

, , +9

Eculizumab improves fatigue in refractory generalized myasthenia gravis

Henning Andersen, Renato Mantegazza, Jing Jing Wang et al. · Quality of Life Research · 2019 · 56 citations · Full text

, , +14

Response to eculizumab in patients with myasthenia gravis recently treated with chronic IVIg: a subgroup analysis of REGAIN and its open-label extension study

Saiju Jacob, Hiroyuki Murai, Kimiaki Utsugisawa et al. · Therapeutic Advances in Neurological Disorders · 2020 · 26 citations · Full text

, , +13

Long-term efficacy and safety of eculizumab in Japanese patients with generalized myasthenia gravis: A subgroup analysis of the REGAIN open-label extension study

Hiroyuki Murai, Akiyuki Uzawa, Yasushi Suzuki et al. · Journal of the Neurological Sciences · 2019 · 23 citations · Full text

, , +14

1–5 of 7